obesity drug news today glp-1 oct 27 2025 2024 was a record year for trials and is already poised to take over Popular GLP-1 medications may have

This article examines clinical safety data, GI mechanisms, and how genetic predispositions may influence medication tolerance in IBD patients see

GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC50 of 0.2 nM

Autoimmune thyroid disease (AITD), including Hashimoto thyroiditis and Graves disease, represents the most prevalent organ-specific autoimmunity and a major cause of thyroid dysfunction worldwide

Learn what results to expect on GLP-1/GIP medications after 1, 3, and 6 months

Weight Support*

This review describes the basic and clinical pharmacology of orally administered semaglutide